Published in final edited form as:

Pediatr Infect Dis J. 2016 December ; 35(12): e378–e383. doi:10.1097/INF.0000000000001319.

Effect of Lopinavir and Nevirapine Concentrations on Viral Outcomes in Protease Inhibitor-Experienced HIV-Infected Children

Retsilisitsoe R. Moholisa¹, Michael Schomaker², Louise Kuhn³, Sandra Castel¹, Lubbe Wiesner¹, Ashraf Coovadia⁴, Renate Strehlau⁴, Faezah Patel⁴, Francoise Pinillos⁴, Elaine J. Abrams⁵, Gary Maartens^{1,6}, and Helen McIlleron^{1,6}

¹Division of Clinical Pharmacology, Department of Medicine, University of Cape Town ²Centre for Infectious Diseases Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town ³Gertrude H Sergievsky Center, College of Physicians and Surgeons, and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York ⁴Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital, Faculty of Health Sciences, University of Witwatersrand ⁵ICAP, Mailman School of Public Health, and College of Physicians & Surgeons, Columbia University, New York ⁶Institute of Infectious Diseases and Molecular Medicine, University of Cape Town

Abstract

Background—Adequate exposure to antiretroviral drugs is necessary to achieve and sustain viral suppression. However, the target antiretroviral concentrations associated with long term viral suppression have not been adequately defined in children.

Aim—We assessed the relationship between plasma lopinavir or nevirapine concentrations and the risk of subsequent viremia in children initially suppressed on antiretroviral therapy.

Methods—After an induction phase of antiretroviral treatment, 195 children with viral suppression (viral load < 400 copies/mL) were randomized to remain on a lopinavir/ritonavir-based regimen or to switch to a nevirapine-based regimen (together with lamivudine and stavudine). Viral load and lopinavir or nevirapine concentrations were measured at clinic visits 4, 8, 12, 16, 20, 24, 36, 52, 64 and 76 weeks post-randomization. Cox multiple failure event models were used to estimate the effects of drug concentrations on the hazard of viremia (viral load >50 copies/mL)

Results—At randomization, the median (IQR) age, CD4⁺ T-Lymphocyte percentage, weight-for-age and weight-for-height z-scores were 19 (16–24) months, 29 (23–37) %, –0.6(–1.3 to 0.2) and –3.2 (–4.1 to –2.1) respectively. The proportion of children with viral load 51–400 copies/mL at randomization was 43%. The hazard of subsequent viremia during follow-up was increased for lopinavir concentrations <1mg/L vs 1mg/L (adjusted hazard ratio 0.62 [95% CI, 0.40–0.94]) and for children with viral loads 51–400 copies/mL at randomization. Nevirapine concentrations were not significantly associated with subsequent viremia.

Conclusion—Plasma lopinavir concentrations predicted viral outcomes in children receiving lopinavir-based antiretroviral therapy. Our findings support a minimum target concentration of 1mg/L of lopinavir to ensure sustained viral suppression.

Keywords

Therapeutic Drug monitoring; Pharmacokinetics; Viremia

Introduction

Combination antiretroviral therapy (ART) has significantly improved survival and quality of life of HIV infected children worldwide¹. The maintenance of adequate drug exposures is necessary to prevent viral resistance and ART failure, and high levels of adherence are critical for maintaining viral suppression^{2,3}.

Current ART treatment guidelines for HIV-infected children recommend combination therapy of dual nucleoside analogue reverse transcriptase inhibitor (NRTI) combined with either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a boosted protease inhibitor (PI). Nevirapine (NVP) has a low barrier to develop viral resistance. Suboptimal NVP concentrations have been shown to select for the development of drug resistance mutations⁴. An ART regimen including the co-formulated PI lopinavir/ritonavir (LPV/r) has been shown to be superior to a NVP-based regimen for treating infants exposed to NVP perinatally⁵. LPV/r has a high barrier for resistance, however, the oral suspension of LPV/r has poor palatability which may result in poor treatment adherence^{6,7}.

Based largely on studies in adults, minimum trough concentrations of 1mg/L and 3mg/L are recommended for LPV and NVP, respectively^{8,9}. Therapeutic drug monitoring is recommended by some guidelines for children on LPV or NVP¹⁰, as the plasma concentrations of both drugs are highly variable even after observed doses. However few data exist on the relationship between plasma drug concentrations of LPV or NVP, and viral response in children.

We measured serial LPV and NVP concentrations from stored plasma in children enrolled in a clinical trial^{7,10}. Once they had achieved viral suppression (<400 copies/mL), children were randomized to continue LPV/r or to switch to NVP. The purpose of our analysis is to evaluate the plasma LPV and NVP concentrations associated with maintenance of viral suppression.

Methods

Plasma LPV and NVP concentrations were retrospectively analyzed in samples collected from participants of the Neverest2 trial at clinic visits during the post-randomization period^{7,11}. The Neverest2 trial was a randomized open-label clinical trial investigating treatment options for NVP exposed children who initiated PI-based ART when less than 24 months of age. HIV infected children attending the Rahima Moosa Mother and Child Hospital, Johannesburg, South Africa, who achieved a viral load (VL) <400 copies/mL for at least 2 consecutive visits on LPV-based ART were eligible for randomization. Once criteria

for randomization were met, the children were randomized 1:1 to continue their LPV/r regimen or switch LPV/r to NVP. NVP (Viramune® oral solution, Boehringer Ingelheim) was introduced at 120 mg/m² once daily for the first 2 weeks and thereafter at 200mg/m² 12 hourly. Children randomized to continue LPV/r (Kaletra® oral solution, Abbott Laboratories, USA), received doses of 230 mg/m² 12 hourly. Lamivudine and stavudine were used as the other two drugs. Doses were adjusted according to the growth of the children at each visit. Both NVP and LPV groups received additional adherence counselling, including specific instructions concerning the lead-in schedule and possible adverse effects for children switching to NVP.

Data collected at randomization included age, sex, VL and CD4⁺ T lymphocyte percentage (CD4%). Weight-for-age z-score (WAZ) and height-for-age z-score (HAZ) at randomization were calculated using WHO software⁷. In both groups, blood samples were collected at randomization and at 4, 8, 12, 16, 20, 24, 36, 52, 64 and 76 weeks post-randomisation and at unscheduled clinic visits. Blood samples collected at each visit post-randomization were used to measure VL (post-randomization viremia was defined as VL >50 copies/mL), and LPV or NVP concentrations. The time of blood sample collection was documented, as was the time of the morning dose of antiretrovirals, as reported by the caregiver. Caregivers were requested to return medication bottles at each visit. The bottles were weighed and the contents reconciled with the expected usage of each medication to determine the degree of adherence. Adherence was defined as returning less than 20% of the expected volume of any of the three drugs, whereas returning more than 20% was defined as non-adherence. In children who were diagnosed with TB after randomization, concomitant TB treatment was recorded at each visit. After 76 weeks, all children were enrolled in an extended follow-up period during which clinical care was provided and monitored.

Laboratory Methods

Plasma LPV and NVP concentrations were assayed using validated liquid chromatography tandem mass spectrometry methods developed in the Division of Clinical Pharmacology, Cape Town, South Africa. An AB Sciex 4000 mass spectrometer was operated at unit resolution in the multiple reaction monitoring (MRM) mode. The validated concentration range for the LPV assay was 0.16 mg/L to 20 mg/L and that for NVP was 0.1 mg/L to 15 mg/L. Inter- and intra-day coefficients of variation were below 10% for all quality control concentrations. The laboratory, at which the concentrations were assayed, participates in the International Inter-laboratory Pharmacology Quality Control Program, the AIDS Clinical Trial Group (ACTG).

Statistical Analysis

Children with a WAZ > -2 SD below the norm, were categorized as underweight. HAZ < -2 was regarded as indicating stunting. Immunity at randomization was categorized as low (CD4% less than 25%) or high (CD4% greater than or equal to 25%) whilst VL was categorized as low level viremia (VL 51–400 copies/mL) or suppressed (VL ≤ 50 copies/mL). TB treatment was a dichotomous variable (present or absent at each post-randomization visit). LPV and NVP concentrations below the limit of quantification (BLQ) were assigned values of 0.08 and 0.05 mg/L respectively (half the limit of quantification).

Characteristics at randomization were described with summary statistics (median, interquartile range (IQR) and proportions).

Cox proportional hazard regression for multiple failure events was used to estimate the crude and adjusted hazard ratios for viremia (VL >50 copies/mL) associated with the following pre-determined variables: CD4%, age, WAZ, HAZ and VL at randomization, TB treatment post-randomization, and LPV or NVP concentration at the current visit. In secondary analyses, we determined the crude and adjusted hazards of viremia associated with LPV or NVP concentration at the previous visit, and the crude and adjusted hazards of viremia associated with the average of two drug concentrations, derived from the current and prior visits, respectively. To account for missing CD4% and adherence data, as well as LPV and NVP concentrations, 10 multiple imputations were conducted using the Amelia II software package in R¹². The imputation model included variables for WAZ, HAZ, VL and CD4% at the time of randomization as well as repeated measures of adherence, TB treatment, and NVP and LPV concentrations during follow-up, along with the time (weeks on treatment). All results in our crude and adjusted analyses are based on the imputed datasets and combined using Rubin's rules¹³. Hazard ratios (HR) are reported together with the 95% confidence intervals (CI). Akaike information criterion (AIC) for each imputed dataset was used to compare all the adjusted models.

We modelled the effect of LPV and NVP on the hazard not only linearly but also using binary cut-offs for drug concentrations. Mixed effects logistic regression models were used to describe the hazard of viremia (VL >50 copies/mL) for concentrations below each cut-off value respectively compared to higher concentrations. Multivariate models were used to adjust for the time post-randomization (in weeks), and clustering by individual was used. We compared LPV cut-offs [0.5, 1, 2, 3, 4, 5 & 6 mg/L] and NVP cut-offs [2, 3, 4, 5, 6, 7 & 9 mg/L] by means of generalized cross validation (GCV)¹⁴.

To graphically display the non-linear effects of LPV and NVP concentrations on the hazard of viremia we used penalized splines¹⁵.

Finally, we compared two adjusted models by means of AIC in each imputed dataset; the first model included all variables at randomization and LPV or NVP concentrations at each visit, whereas the second model included all variables at randomization and percentage adherence at each visit in both the LPV and the NVP groups. Data was analysed using the statistical software package R¹⁶.

Results

Study Population

A total of 195 children from the initial 322 children were enrolled in the post-randomization phase of the NEVEREST2 study. Of the 195 children, 96 were switched to NVP whilst 99 remained on a LPV regimen. Table 1 shows the characteristics of children in both groups in the study at randomization, and indicates missing data. The characteristics in the two groups were similar.

Plasma Lopinavir and Nevirapine Concentrations

For the LPV group, a total of 1134 plasma samples from 99 children with a median of 8 samples per child were collected from 3 weeks to 209 weeks post-randomization (Supplementary Figure 1A). The blood was sampled a median 3.00 (IQR 2.00–3.91) hours after the reported dose of antiretrovirals, and 7% of the samples were BLQ with 6% missing. The median population LPV concentrations determined at 24, 50, 76, and 100 and 150 weeks, respectively, show a non-significant trend to increase over time (Table 2).

For the NVP group, a total of 764 samples plasma samples from 96 children, with a median of 6 samples per child, were collected from 3 to 196 weeks post-randomization. For the NVP group, a total of 764 samples plasma samples from 96 children, with a median of 6 samples per child, were collected from 3 to 196 weeks post-randomization. The median time of sampling was 3.00 (IQR 2.17–3.92) hours after the reported dose, and 1% of samples were BLQ and 9% were missing. The median NVP concentrations were similar across all visits (Table 2). Five children had exceptionally high NVP concentrations i.e. NVP concentrations consistently above 40 mg/L for an average of 2 visits. The data for these five children were excluded in subsequent analyses. Two of these children had TB post-randomization and were switched to another ART regimen. One child who experienced toxicity and one child with viral failure were withdrawn, and one child was lost to follow-up.

Predictors of Viremia (Viral load >50 copies/mL) in the LVP Group

As shown in Table 3, the risk of viremia (VL >50 copies/mL) was estimated to be reduced by 5% for each 1 mg/L increment in the current visit LPV concentration (HR: 0.95 [95% CI 0.92, 0.98]; $P<0.01$). Children with low level viremia (VL 51–400 copies/mL) at the time of randomization had a 2.62-fold increased risk of viremia (HR: 2.62 [95% CI 1.62, 4.24]; $P<0.01$) (Table 3) compared to children with VL <50 copies/mL. After adjusting for other covariates both LPV concentrations (HR: 0.96 [95% CI 0.94, 0.99]; $P=0.01$) and VL at randomization (HR: 2.66 [95% CI 1.68, 4.22]; $P<0.01$) remained significant predictors of post-randomization viremia. We found the average of two LPV concentrations (at the current visit and previous visit, respectively) were predictive of viremia in the crude (HR: 0.94 [95% CI 0.91, 0.98]; $P<0.01$) and adjusted (HR: 0.96 [95% CI 0.92, 1.00; $P=0.05$) models (data not shown), whereas LVP concentrations at the previous visit was less predictive of viremia in both crude (HR: 0.98 [95% CI 0.96, 1.01]; $P=0.15$) and adjusted (HR: 0.99 [95% CI 0.96, 1.02]; $P=0.36$) models (data not shown). The effect of low level viremia at randomization remained significant in all models. When we compared the three models by means of AIC in each imputed dataset, we showed that the models which included current visit LPV concentrations or the average of LPV concentrations at two visits described the data better than the model with previous visit LPV concentrations. Due to high percentage of missing data (24%), adherence was not included in the primary analysis. However, in a secondary analysis we compared two models using AIC in each imputed dataset, where the first model included current LPV concentrations and the second model included recorded adherence (data not shown). In each imputed dataset the model including LPV (low AIC values) was more predictive of viremia compared to model with adherence. We used predictive modelling to compare logistic regression models (using GCV values) and thereby evaluating the effects of various cut-off concentrations, we showed that a cut-off concentration of

1mg/L best predicted viremia (Figure 1). A separate Cox regression model, in which LPV concentrations were dichotomized with a cut-off of 1 mg/L (Table 3), a 41% reduction in the risk of viremia in children with LPV concentrations ≥ 1 mg/L compared to children with LPV concentrations <1 mg/L was shown. These associations were preserved in the adjusted models in which low level viremia at randomization was also significantly associated with increased hazard of viremia.

Predictors of Viremia (Viral load >50 copies/ml) in the NVP Group

We assessed the risk of viremia (VL >50 copies/mL) in the NVP group using Cox proportional hazards models. Neither current visit concentrations (Table 4), previous visit (**data not shown**) NVP concentrations nor average of two NVP (**data not shown**) concentrations taken at the current and previous visits respectively, were associated with the risk of viremia in crude or adjusted models. We compared the three models by means of AIC in each imputed dataset and showed that the model with current visit and average of two visit NVP concentrations described the data similarly but better compared with the model with previous visit NVP concentration. Consistently high NVP concentrations were measured in 5 children, these outlying observations were excluded in the primary analysis. However in the sensitivity analysis we included the 5 children and they were influential, biasing results to significance (**data not shown**). Due to high percentage of missing data (29%), adherence was not included in the primary analysis. As for the LPV arm, we showed that current visit NVP concentrations described the data better than recorded adherence in a sensitivity analysis (data not shown). Based on GCV values for the logistic regression evaluating the effect of NVP concentration thresholds, an NVP concentration cut-off values of 5mg/L best predicted viremia in the respective arm (Figure 1). A separate Cox regression model was performed where NVP was dichotomized to evaluate the effects of NVP concentrations ≥ 5 mg/L vs. <5 mg/L. While not statistically significant, there was a trend to a reduction in the risk of viremia in children with NVP concentrations ≥ 5 mg/L (crude HR: 0.64[95% CI 0.33, 1.27]; $P=0.20$) (Table 4)

Discussion

We evaluated the risk of viremia (VL >50 copies/mL) in treatment experienced children achieving viral suppression (VL <400 copies/mL) after switching to NVP or remaining on LVP/r. In keeping with our analysis of the pre-randomization phase of the same study¹⁷, higher LPV concentrations are associated with sustained viral suppression. Our data suggests that children with LPV concentrations >1 mg/L have a reduction in the risk of viremia of about 40%, compared to children with LPV <1 mg/L. In children established on ART a LPV concentration of 1 mg/L (taken 2–4 hours after the claimed morning dose time) may therefore be used as a threshold for therapeutic drug monitoring (TDM). We compared different concentrations cut-offs for LPV and NVP, and found 1mg/L and 5mg/L, respectively, to be the most predictive threshold values for the risk of viremia. However, the association between NVP concentration <5 mg/L and viremia was not significant in the regression model. This finding is consistent with other reports that NVP concentrations do not predict viral response⁹. We acknowledge that there was some model selection uncertainty in the choice of the best cut-off. We used cross validation to find a model that

minimizes the expected prediction error; however, it may well be that models with other cut-offs have a good predictive ability too^{18,19}.

Pre-existing drug resistance most likely accounts for the viremia in the NVP group as all children enrolled in this trial had past exposure to single-dose NVP used for PMTCT^{7,11}. Low level viremia at randomization was associated with increased risk of ongoing viremia. This finding was more marked in children on the LPV/r-based regimen, and was independent of other effects captured by the multivariate models. This suggests that the risk of future viremia, conferred by low level viremia at randomization was not modified by LPV exposure post-randomization, however our study was not designed to evaluate whether interventions to increase LPV exposure in those children with low level viremia would lead to suppression. In contrast to NVP, a high proportion (55–100%) of LPV concentrations below the threshold of 1 mg/L were below the quantifiable limit of the LPV assay (0.16 mg/L) across all visits (Table 2). This suggests that poor adherence accounts for most LPV concentrations <1 mg/L, which were associated with viremia, and supports efforts to develop LPV/r formulations with improved palatability. Sensitivity analyses, in which LPV concentrations below the quantifiable limit were excluded, support the notion that the very low LPV concentrations drive the association with viremia (**data not shown**). That poor outcomes was related to drug exposure in three of five children with exceptionally high NVP concentrations cannot be excluded, and whether the high concentrations were related to genetic polymorphisms of genes regulating the disposition of NVP is the subject of further investigation. This study has several limitations that are worth highlighting. Firstly, antiretroviral drug dosing was not directly observed therefore, our only measure of adherence was caregiver-reported adherence, which likely contributed to intra-individual variability in LPV and NVP concentrations. Secondly, the time of sampling in relation to the dose is a key determinant of drug concentration. In this study we did not observe the time of dosing and this was not included in our analysis. Despite this limitation, we have shown that LPV concentrations taken after 3.0 (2.0–3.9) hours after the last dose predict viremia, suggesting that a sample taken at a routine morning clinic can be used for LPV concentration monitoring. Thirdly, there was missing data, which was dealt with by multiple imputation. Previous studies have shown multiple imputation to be superior to complete case analysis in which only patients with complete data across all variables are analyzed²⁰. If data are missing at random and thus the probability for value to be missing randomly depends only on observed quantities, then no bias is introduced. We assumed data to be missing at random and found it to be a reasonable assumption given that the missing data related mainly to insufficient sample volumes or lost samples. Lastly, we acknowledge that there was some model uncertainty in the choice of the best cut-off. Nonetheless, we used generalized cross validation to find a model that minimizes the expected prediction error, however, it may well be that other models with other cut-offs have good predictive ability too. Strengths of the study include a relatively large sample size with viral load and plasma drug concentration measurements at repeated clinic visits, which made it possible to assess the relationship between each child's LPV or NVP concentration and their VL at successive intervals. Measuring drug concentrations can be used as an effective tool in ensuring that therapeutic targets of ART are met^{21,22}. However, TDM is not routinely used in any low and middle income country programs to our knowledge. There is also currently insufficient

knowledge of target plasma concentrations in children. Moreover, although minimum trough concentrations for LPV and NVP of 1 mg/L (in treatment naïve children) and 3 mg/L, respectively, have been recommended^{7,20}, it is challenging to obtain a sample 12 hours post dose in clinical practice. Our findings suggest that a single sample taken 2–4 hours after the dose is a useful predictor of viremia, at least for LPV, and can be used for TDM.

In conclusion, LPV concentrations were associated with the hazard of viremia. Our analysis suggests that LPV plasma concentration monitoring at a routine clinic visit may be a useful tool in identifying sub-therapeutic antiretroviral concentrations in children, and thereby assist with adherence support.

Acknowledgments

National Institutes of Child Health and Human Development (NICHD) HD 47177 and Secure the Future Foundation RES 219(LK). South African National Research Foundation (RM, and grant 90729 to HM), Health and Welfare Sector Education and Training Authority and Carnegie Corporation (both RM). NIH grant UM1 AI 106701 through the AIDS Clinical Trials Group. Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number UM1 AI068634, UM1 AI068636 and UM1 AI106701. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

References

1. Rakhmanina NY, van den Anker JN, Soldin SJ, van Schaik RH, Mordwinkin N, Neely MN. Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents? *Ther Drug Monit.* 2010; 32:273–81. [PubMed: 20445485]
2. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. *Clin Infect Dis.* 2002; 34:1115–21. [PubMed: 11915001]
3. Liu H, Miller LG, Hays RD, et al. Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. *J Acquir Immune Defic Syndr.* 2006; 41:315–22. [PubMed: 16540932]
4. Requena DG, De Bonora S, Garazzino S, et al. Nevirapine Plasma Exposure Affects both Durability of Viral Suppression and Selection of Nevirapine Primary Resistance Mutations in a Clinical Setting. *Nevirapine Plasma Exposure Affects both Durability of Viral Suppression and Selection of Nevirapine Prim.* 2005; 49:3966–9.
5. Lockman S, Hughes MD, McIntyre J, et al. Antiretroviral therapies in women after single-dose nevirapine exposure. *N Engl J Med.* 2010; 363:1499–509. [PubMed: 20942666]
6. Rudin C, Wolbers M, Nadal D, Rickenbach M, Bucher HC. Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children. *Arch Dis Child.* 2010; 95:478–81. [PubMed: 20501542]
7. Coovadia A, Abrams EJ, Stehlau R, et al. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. *JAMA.* 2010; 304:1082–90. [PubMed: 20823434]
8. la Porte CJL, Back DJ, Blaschke T, Fletcher CV, et al. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents Fosamprenavir. *Antivir Ther.* 2006; 3
9. Leth F, Van Kappelhoff BS, Johnson D, et al. Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. *AIDS Res Hum Retroviruses.* 2006; 22:232–9. [PubMed: 16545009]
10. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children; Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Aug 16. 2010 p. 1-219. Available at <http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf>. Accessed August 11, 2012

11. Kuhn L, Coovadia A, Strehlau R, et al. Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. *Lancet Infect Dis.* 2012; 12:521–30. [PubMed: 22424722]
12. Honaker J, King G, Blackwell M. AMELIA II: A Program for Missing Data. 2011:1–54.
13. Rubin DB. Multiple Imputation after 18+ Years. *J Am Stat Assoc.* 1996; 91:473–489.
14. Golub GH, Heath MT, Wahba G. Generalized cross-validation as a method for choosing a good ridge parameter. *Technometrics.* 1979; 21:215–223.
15. Eilers PHC, Marx BD. Flexible smoothing with B-splines and penalties. *Statistical Science.* 1996; 11:89–102.
16. R Development Core Team. R: a language and environment for statistical computing. Version 3.0.2. Vienna: R Foundation for Statistical Computing; 2010.
17. Moholisa RR, Schomaker M, Kuhn L, et al. Plasma lopinavir concentrations predict virological failure in a cohort of South African children initiating a protease-inhibitor-based regimen. *Antivir Ther.* 2014; 19:399–406. [PubMed: 24518130]
18. Schomaker M, Heumann C. Model selection and model averaging after multiple imputation. *Comput Stat Data Anal.* 2014; 71:758–770.
19. Hoeting, Ja; Madigan, D.; Raftery, AE.; Volinsky, CT. Bayesian model averaging: a tutorial. *Stat Sci.* 1999; 14:382–417.
20. Rubin DB. Multiple Imputation After 18 + Years. *J Am Stat Assoc.* 2012; 91:473–489.
21. Fraaij PLA, Rakhmanina N, Burger DM, de Groot R. Therapeutic drug monitoring in children with HIV/AIDS. *Ther Drug Monit.* 2004; 26:122–6. [PubMed: 15228151]
22. Giaquinto C, Anabwani G, Feiterna-Sperling C, et al. Steady-State Pharmacokinetics of Nevirapine Extended-Release Tablets in HIV-1 Infected Children and Adolescents: An Open-Label, Multiple Dose, Cross-Over Study. *Pediatr Infect Dis J.* Dec 30.2013

Figure 1.

Non-linear effect of lopinavir and nevirapine concentrations on the hazard of viremia with determination of cut-offs using generalized cross validation. Left panel demonstrates lopinavir and the right panel presents nevirapine. LPV Cut-off, lopinavir concentrations cut-offs; NVP Cut-off, nevirapine concentrations cut-offs; GCV, generalized cross validation values

Characteristics at randomization of the 195 HIV-infected children remaining on a lopinavir/ritonavir-based regimen or switched to nevirapine-based antiretroviral therapy

Table 1

		Characteristics of children in the LPV group (n=99)				Characteristics of children in the NVP group (n=96)			
Variable		Median	IQR	Missing Data	Median	IQR	Missing Data		
Age(months)		20	16-25	0	18	15-22.25	0		
VL 50 copies/ml		55(56%)		0	53(55%)		0		
VL51-400 copies/ml		44(44%)			43(45%)				
CD4%		28.05	21.65-35.20	4	29.55	22.95-36.70	3		
WAZ		-0.60	-1.26 to 0.07	0	-0.60	-1.17 to -0.13	0		
HAZ		-3.18	-3.97 to -1.97	0	-2.80	-2.10 to -4.05	0		
TB Treatment									
No		86(86%)			91(94%)				
Yes		13(14%)		0	6(6%)		0		

Data are in Median (IQR) or n(%). Age, Age at randomization; VL, viral load at randomization; CD4%, CD4⁺ T lymphocyte percentage at randomization; WAZ, weight for age z-scores at randomization; HAZ, height for age z-score at randomization; TB Treatment, concomitant tuberculosis treatment post-randomization.

Lopinavir and nevirapine concentrations, time of sampling, body weight and dose by study week

Table 2

Characteristics	LPV Group						NVP Group					
	24(n=99)	50(n=94)	76(n=99)	100(n=98)	124(n=78)	150+(n=64)	24(n=92)	50(n=75)	76(n=71)	100(n=61)	124(n=44)	150+(n=34)
Weeks												
Median Drug [mg/L]	8.92 (5.34–12.9)	9.19 (5.51–13.9)	10.20 (6.68–13.9)	9.69 (6.28–13.9)	11.60 (7.90–17.2)	11.90 (8.81–14.7)	9.1 (8.4–15.2)	9.51 (7.2–11.4)	11.2 (8.3–14.2)	11.85 (9.2–16.1)	12.4 (9.4–14.7)	11.85 (8.04–16)
% Samples between LLQ and 1 mg/L for LPV, between LLQ and 3 mg/L for NVP	8	12	10	9	9	7	3	6	2	4	3	7
% BLQ	6	12	9	5	9	6	0	2	1	3	1	1
Time after Dose (h)	3 (2.50–4.25)	3.00 (2.18–4.00)	3.08 (2.33–4.00)	3.33 (2.25–4.25)	3.00 (2.25–3.75)	2.83 (2.00–3.67)	3.08 (2.25–3.92)	3.17 (2.58–4.17)	3.33 (2.50–4.17)	3.08 (2.25–4.17)	3.25 (2.58–3.88)	3.00 (2.33–4.00)
Total Body Weight (kg)	11 (10–12)	12 (11–13)	13 (12–14)	13 (12–16)	16 (15–18)	17 (16–19)	11 (10–13)	12 (10–13)	13 (12–14)	14 (12–15)	15 (13–16)	17 (15–18)
Dose (mg/m ²)	228 (222–232)	225 (219–231)	226 (221–231)	226 (223–232)	227 (223–231)	227 (223–231)	196 (193–200)	196 (192–200)	195 (192–198)	197 (193–199)	197 (192–199)	197 (195–200)

Data are in Median (IQR), unless otherwise stated; LLQ, lower limit of quantification; BLQ, below the assay limit of quantification; LPV, lopinavir; NVP, nevirapine

Table 3

Cox proportional hazards regression analysis describing the risk of viremia (VL >50 copies/mL) post-randomization in 99 children randomized to LPV/r-based treatment.

Characteristic	Crude			Adjusted			Characteristic	Crude			Adjusted		
	HR	95%CI	P Value	HR	95%CI	P Value		HR	95%CI	P Value	HR	95%CI	P Value
LPV (mg/L)	0.95	0.92–0.98	<0.01	0.96	0.94–99	0.01	LPV <1 mg/L	Reference			Reference		
Age 20 months	Reference			Reference			LPV 1 mg/L	0.59	0.40–0.94	0.03	0.62	0.40–0.95	0.03
Age <20 months	1.48	0.91–2.39	0.11	1.47	0.92–2.34	0.11	Age 20 months	Reference			Reference		
Normal WAZ	Reference			Reference			Age <20 months	1.48	0.91–2.39	0.34	1.47	0.92–2.34	0.09
Underweight	2.36	0.77–7.25	0.13	2.62	0.94–7.24	0.06	Normal WAZ	Reference			Reference		
Normal HAZ	Reference			Reference			Underweight	2.36	0.77–7.25	0.13	2.90	1.04–8.42	0.05
Stunted	0.64	0.36–1.12	0.12	0.78	0.43–1.39	0.40	Normal HAZ	Reference			Reference		
VL 50	Reference			Reference			Stunted	0.64	0.36–1.12	0.16	0.76	0.43–1.34	0.34
VL 51–400	2.62	1.62–4.24	<0.01	2.66	1.68–4.22	<0.01	VL 50	Reference			Reference		
CD4% ≥25	Reference			Reference			VL 51–400	2.62	1.62–4.24	<0.01	2.73	1.72–4.33	<0.01
CD4% <25	1.25	0.75–2.06	0.38	1.05	0.66–1.66	0.85	CD4% ≥25	Reference			Reference		
TB Treatment (No)	Reference			Reference			CD4% <25	1.25	0.75–2.06	0.28	1.05	0.66–1.66	0.85
TB Treatment (Yes)	0.36	0.13–1.05	0.07	0.41	0.15–1.15	0.09	TB Treatment (No)	Reference			Reference		
							TB Treatment (Yes)	0.36	0.13–1.05	0.07	0.41	0.15–1.15	0.09

HR, hazard ratio; LPV, lopinavir concentration at each visit; Age, age at randomization; VL, viral load at randomization; CD4% T lymphocyte percentage at randomization; WAZ, weight for age z-scores at randomization; HAZ, height for age z-score at randomization; TB Treatment, concomitant tuberculosis treatment post-randomization.

Table 4

Cox proportional hazards regression model describing the risk of viremia (VL >50 copies/mL) in children (n=96) associated with current visit plasma nevirapine concentrations.

Characteristic	Crude			Adjusted			Characteristic			Crude			Adjusted		
	HR	95%CI	P Value	HR	95%CI	P Value				HR	95%CI	P Value	HR	95%CI	P Value
NVP(mg/L)	0.95	0.90–1.01	0.11	0.96	0.91–1.01	0.13	NVP 5mg/L			Reference			Reference		
Age 18 months	Reference			Reference			NVP <5mg/L			0.64	0.33–1.27	0.20	0.69	0.33–1.41	0.31
Age <18 months	1.31	0.69–2.47	0.42	1.48	0.77–2.84	0.26	Age 18 months			Reference			Reference		
Normal WAZ	Reference			Reference			Age <18 months			1.31	0.69–2.47	0.42	1.48	0.77–2.82	0.24
Underweight	1.28	0.37–4.44	0.69	1.39	0.34–5.62	0.64	WAZ(normal)			Reference			Reference		
Normal HAZ	Reference			Reference			WAZ(advanced)			1.28	0.37–4.44	0.69	1.43	0.36–5.64	0.61
Stunted	0.87	0.46–1.66	0.67	0.88	0.47–1.65	0.67	HAZ(normal)			Reference			Reference		
VL 50	Reference			Reference			HAZ(advanced)			0.87	0.46–1.66	0.67	0.90	0.47–1.73	0.76
VL >50	1.69	0.91–3.16	0.09	1.75	0.92–3.35	0.09	VL 50			Reference			Reference		
CD4% 25	Reference			Reference			VL >50			1.69	0.91–3.16	0.09	1.79	0.93–3.44	0.08
CD4% <25	1.21	0.61–2.49	0.59	1.23	0.63–2.39	0.64	CD4% 25			Reference			Reference		
TB Treatment (No)	Reference			Reference			CD4% <25			1.21	0.61–2.49	0.59	1.19	0.61–2.31	0.61
TB Treatment(Yes)	1.12	0.34–3.64	0.86	1.19	0.28–5.33	0.82	TB Treatment (No)			Reference			Reference		
							TB Treatment (Yes)			1.12	0.34–3.64	0.86	1.15	0.26–5.11	0.85

HR, hazard ratio; NVP, nevirapine concentration at each visit; Age, Age at randomization; VL, viral load at randomization; CD4% T lymphocyte percentage at randomization; WAZ, weight for age z-scores at randomization; HAZ, height for age z-score at randomization; TB Treatment, concomitant tuberculosis treatment post-randomization